The global asthma therapeutics market size was US$ 17.9 billion in 2021 and is forecast to reach US$ 27.63 Billion by 2030, registering a compound annual growth rate (CAGR) of 2.13% during the forecast period from 2022 to 2030.
Pharmaceutical medications used to treat asthma are referred to as asthma therapies. Pollution, allergens, and dust are some of the common indoor and outdoor causes of asthma. These medications, which often consist of corticosteroids, long-acting beta-agonists (LABA), methylxanthine, immunomodulators, and leukotriene modifiers, are bronchodilators and anti-inflammatory agents. A variety of injectable, oral, and inhalation combination treatment medications are also employed. These medications widen the pulmonary opening and facilitate airflow, which enhances breathing. They also help in the easy removal of pulmonary mucus by coughing.
Factors Affecting the Global Market Growth
Impact Analysis of COVID-19
Asthma treatment is more in demand because COVID-19 and asthma are both respiratory disorders. This is partly due to the fact that asthma is the most prevalent chronic illness, with a sizable patient population pool, and COVID-19 had to exacerbate asthma symptoms in those who already have them, necessitating the need for effective asthma treatment. The Centers for Disease Control and Prevention (CDC) has recommended increased vigilance for asthma patients and provided particular instructions for those receiving treatment for asthma during the 2019–2020 coronavirus pandemic. This has increased demand for cutting-edge asthma medications, which fueled this market's expansion.
Regional Overview
North America held a significant share of the global asthma therapeutics market. Some of the key factors contributing to this region's substantial revenue share are the expanding usage of inhaled therapies, the greater awareness of treatment choices, and the rising incidence rate of asthma. The growing elderly population in the United States will contribute to the expansion of the regional market by making them more prone to developing respiratory disorders like asthma.
Contrary, the Asia Pacific region is predicted to grow at the highest CAGR during the forecast period. This is due to the generic competition, rising asthma prevalence, and the need for cost-effective treatment for patients.
Prominent Companies
Some of the leading competitors in the global asthma therapeutics market are:
Segmentation Outline
The global asthma therapeutics market segmentation focuses on Drug Class, Product Type, Treatment Type, Route of Administration, and Region.
By Drug Class
By Product Type
By Treatment Type
By Route of Administration
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL ASTHMA THERAPEUTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL ASTHMA THERAPEUTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL ASTHMA THERAPEUTICS MARKET, BY DRUG CLASS
5.1 OVERVIEW
5.2 ANTI-INFLAMMATORY DRUGS
BRONCHODILATORS
COMBINATION THERAPIES
6 GLOBAL ASTHMA THERAPEUTICS MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 INHALERS
6.2.1 DRY POWDER INHALERS
6.2.2 METERED DOSE INHALERS
6.2.3 SOFT MIST INHALERS
6.3 NEBULIZERS
6.3.1 PNEUMATIC NEBULIZERS
6.3.2 ULTRASONIC NEBULIZERS
6.3.3 MESH NEBULIZERS
7 GLOBAL ASTHMA THERAPEUTICS MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 QUICK-RELIEF MEDICATIONS
7.3 LONG-TERM ASTHMA CONTROL MEDICATIONS
8 GLOBAL ASTHMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 INHALATION
8.3 ORAL
8.4 PARENTERAL
9 GLOBAL ASTHMA THERAPEUTICS MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3.1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA
9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA
10 GLOBAL ASTHMA THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES
11 COMPANY PROFILES
11.1 ASTRAZENECA PLC
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS
11.2 ABBOTT LABORATORIES
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS
11.3 AMGEN INC.
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS
11.4 BIOGEN INC.
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS
11.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS
11.6 F. HOFFMANN-LA ROCHE LTD.
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS
11.7 GLAXOSMITHKLINE PLC
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS
11.8. MERCK SHARP & DOHME CORP.
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS
11.9 NOVARTIS INTERNATIONAL AG
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS
11.10 SUNOVION PHARMACEUTICALS INC.
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS
11.11 TEVA PHARMACEUTICAL INDUSTRIES LTD
11.11.1 OVERVIEW
11.11.2 FINANCIAL PERFORMANCE
11.11.3 PRODUCT OUTLOOK
11.11.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved